PharmaSpotter
SearchVendors
HomeSearchDot Compliance Ltd.
Dot Compliance Ltd. logo

Dot Compliance Ltd.

"Ready-to-Use, AI-Powered eQMS for Life Sciences — Built on Salesforce"

Private
Visit Website

Founded

2015

11 years

Employees

201-500

Annual Revenue

Not Disclosed

(2026)

Products

1

Company Overview

Dot Compliance Ltd. is an Israeli-founded, venture-backed life sciences software company that develops a Salesforce-native electronic quality management system (eQMS). Doron Sitbon founded the company in 2015. Commercial headquarters are at 2375 East Camelback Road, Suite 600, Phoenix, Arizona 85016, with R&D in Ra'anana, Israel. The company reports 500+ customers across 30+ countries as of 2026.

The product distributes exclusively through the Salesforce AppExchange (listing ID a0N30000000q6ToEAI, latest release December 1, 2024). The vendor describes it as "100% native Salesforce": the required Salesforce platform license is bundled, so customers do not need a separate Salesforce subscription. It targets pharmaceutical, biotech, medical device, and cosmetics manufacturers with a pre-configured, pre-validated eQMS.

The vendor markets the product as ready-to-use and pre-validated for the fastest time-to-value, and as the first life-sciences vertical AI via Dottie AI, launched April 2023; Dottie AI 5.0 with agentic Personas became generally available April 21, 2026. The company has raised $50M+ in total funding. The most recent round, a $17.5M Series B extension in April 2024, was described as a "significant up-round." Lead investors are IGP Capital (Israel Growth Partners), Vertex Ventures, and TPY Capital.

Pharmaceutical Focus

Dot Compliance is a life-sciences-specialized vendor, not pharma-only and not generalist. It targets pharmaceutical, biotech, medical device, and cosmetics manufacturers with dedicated industry landing pages for each sector. Vendor-stated regulatory coverage applicable to pharma includes 21 CFR Part 11, 21 CFR Part 820, EU Annex 11, and EU GMP; the platform supports ISO 9001, ISO 13485, ISO 14971, and ISO 27001 compliance workflows. DSCSA, FSMA 204, ICH Q7/Q9/Q10, MHRA, PMDA, NMPA, ANVISA, and Health Canada compliance are undisclosed.

Vendor-reported customer count is 500+ across 30 countries. The only pharma reference customer confirmed in vendor-published material is Satsuma Pharmaceuticals, Inc., named in a case study describing its transition from clinical to commercial operations. A secondary aggregator (promptloop.com) lists additional customer names, including Famar (a European CDMO) and Appili; the vendor's own site does not confirm them. Public evidence skews toward emerging biotech, mid-cap pharma, medical device, and CDMO customers rather than top-20 Big Pharma, and no top-20 Big Pharma customer is named publicly. No 483 or Warning Letter names Dot Compliance as system of record.

Industries Served

PharmaceuticalsBiotechnologyMedical DevicesLife Sciences
Financial Overview

Dot Compliance has raised $50M+ in total funding across a seed round, a Series A, a Series B (July 2022, $23M, led by IGP Capital / Israel Growth Partners with Vertex Ventures and TPY Capital), and a Series B extension (April 15, 2024, $17.5M, co-led by IGP Capital and Vertex Ventures with TPY Capital). The press release announcing the round called it "a significant up-round" in its opening paragraph; IGP partner Yoni Levy's own quote in the same release called it "a substantial up-round." Annual revenue, ARR, and profitability are undisclosed. The company is private and has not filed for an IPO or SPAC.

Customer count grew from 400+ at the April 2024 funding announcement to 500+ on the vendor's 2026 About page, roughly 25%+ over about 24 months. IGP Capital and Vertex Ventures backed multiple consecutive rounds, with no down round or bridge round in the record. Dot Compliance has made no acquisitions and has not been acquired.

Products from Dot Compliance Ltd.

Browse all software products offered by Dot Compliance Ltd..

Dot Compliance QMS
QMS
4.0★
(95)

A multi-tenant SaaS eQMS built 100% natively on Salesforce's Force.com platform, delivering pre-configured GxP processes (document control, CAPA, change control, training, audit, supplier, complaint, deviation, risk) with a vendor-supplied validation package, aimed at pharma, biotech, and medical-device quality and IT leaders who need to displace paper or fragmented systems quickly. Packaged tiers: eQMS Xpress (foundation), Compliance Xpand (cross-functional modules), Enterprise Xact (configurable enterprise), and the AI add-on AI Xpert / Dottie AI.

FDA Part 11GxP
Products & Solutions

Dot Compliance delivers a single eQMS suite as a managed Salesforce package. The vendor bundles the required Salesforce platform license, so customers do not need a separate Salesforce subscription. The suite ships in four named editions: eQMS Xpress (core ready-to-use processes — document control, training, CAPA, change, audit, complaints), Compliance Xpand (adds supplier quality, equipment, risk, eBR, quality events), Enterprise Xact (tailored and configured for enterprise requirements), and AI Xpert (the AI-led tier). Process modules listed by the vendor: Document Management, Change Management, Audit Management, Training Management, CAPA Management, Complaint Management, Quality Event Management, Risk Management, Equipment Management, Electronic Batch Record, Supplier Quality Management, Clinical Management, and Regulatory Management.

The flagship AI capability is Dottie AI, which the vendor describes as the industry's first ChatGPT-powered eQMS at its initial launch on April 4, 2023. A third generation added anomaly detection and regulatory risk mitigation, announced December 2024. Dottie AI 5.0, with Dottie Personas — agentic AI specialists authorized by human leaders for specific quality and compliance roles — became generally available April 21, 2026, alongside vendor-stated ISO 42001 (AI management system) certification. The vendor packages vendor-supplied validation documentation with each pre-validated, ready-to-use edition, marketed for the fastest time-to-value. A "hybrid / vendor-agnostic data layer," announced April 2024, would let Dot Compliance AI run atop multiple underlying QMS data sources; whether it has reached general availability is undisclosed.

Partnerships & Technology

Dot Compliance's primary and defining technology partner is Salesforce. The product is 100% native to the Salesforce platform and distributes exclusively via the Salesforce AppExchange (listing ID a0N30000000q6ToEAI, latest release December 1, 2024). Salesforce platform licensing is bundled, removing a separate Salesforce procurement step for buyers. The vendor markets its Salesforce-native architecture as a competitive differentiator and positions a "hybrid, vendor-agnostic" alternative against "vendor lock-in," raised in its April 2024 funding announcement.

No Tier-1 systems-integrator partnership — Deloitte, Accenture, Capgemini, IBM, PwC, EY — is named on the Dot Compliance partner page; the page solicits applications but names no partners. No certified pre-built connector to a specific LIMS, MES, or ERP vendor is published by name, though ERP integration through Salesforce-native connectivity is noted in FAQ materials. No ISPE, PDA, PQG, ASTM, GS1, or USP affiliation is claimed. No Microsoft Azure, AWS, Google Cloud, SAP, Oracle, ServiceNow, or Snowflake partnership is advertised.

Cloud Partners

AWSAzureGCP

Technology Partners

SAPOracleSalesforce
Support & Services

Dot Compliance offers implementation, validation, and training services through an internal professional services organization. A services landing page exists at dotcompliance.com/services/ but publishes no service catalog with SLAs or pricing. Support availability (24/7, regional hours, languages supported) is undisclosed, and no SLA matrix is published.

The vendor's central services positioning is pre-validated, ready-to-use packages with vendor-supplied validation documentation included, which it markets as minimizing customer validation burden at go-live. Named services leaders: Yoni Tsrouya (Global VP Customer Success & Services), Jeni Alexander (Regional VP Services, NA & NPI), and Meirav Hirsch-Galili (Regional VP Professional Services, International). No annual user conference is publicly listed; the closest public customer event is a "New Jersey Hub" customer event scheduled June 1, 2026. Online user community size is undisclosed. No certification program for end users or implementation partners is published.

Implementation
Validation
Training
Credibility & Recognition

Dot Compliance holds vendor-stated certifications in ISO 9001:2015 (quality management), ISO 27001:2022 (information security), ISO 27017:2015 (cloud security), and ISO 42001 (AI management system, announced alongside Dottie AI 5.0 in April 2026). SOC 2 Type II and HITRUST are not claimed. Awards include a Bronze Stevie Award (Company of the Year, Computer Software category, 2024) and a Globes shortlist as one of the 10 most promising Israeli startups in 2024. A secondary aggregator (highperformr.ai) cites inclusion in the "Gartner Hype Cycle for Life Science Clinical Development, 2023"; no primary Gartner source confirms it, and it does not appear on Dot Compliance's own news page. No Gartner Magic Quadrant, Forrester Wave, IDC MarketScape, KLAS, or Verdantix Green Quadrant placement is claimed.

Leadership named on the vendor's About page: Doron Sitbon (Founder & CEO), Amit Innes (CFO), Yuval Nardi, PhD (Chief Data Scientist), Mickey Landkof (General Manager, NA & Global VP of Sales), Tali Weinberg Bloom (VP Sales, EMEA & APAC), Asi Dayan (VP Marketing), Adam Rona (VP Product Management), Tsafrir Shani (VP R&D), Adi Ron (VP Human Resources), and the services leadership trio named above. CEO Doron Sitbon has published bylines in Forbes Technology Council (2024) and Manufacturing Chemist (2025-2026), and has articulated a shift toward "agentic, multi-stage AI processes" and a "data company" positioning.

Market Presence

Dot Compliance's news-and-events page shows an active blog with multiple posts dated April 2026. Corporate press-release cadence over 36 months is low, roughly one major release per year: Series B (July 2022), the Dottie launch (April 2023), the Series B extension (April 2024), and Dottie AI 5.0 (April 2026). Trade-press placements (pharmiweb.com, manufacturingchemist.com) and CEO bylines (Forbes, Manufacturing Chemist) supplement that cadence.

Confirmed 2026 conference appearances: Fierce Biotech Week (May 12–14, 2026), ASQ World Conference on Quality & Improvement (May 17–19, 2026), and American Medical Device Summit (October 26–27, 2026). No DIA Annual, ISPE Annual, or PDA Annual exhibit appears on the events page. The vendor's website does not display a public customer-logo wall; customer evidence is embedded in case studies and LinkedIn content. Product demos are offered; a self-service free trial is undisclosed. LinkedIn presence is active, including a Satsuma case study post and regular company updates; follower count is undisclosed.

Company Details

Headquarters

Phoenix, Arizona, United States

Founded

2015 (11 years in business)

Company Size

201-500 employees

Type

Private

Owned by unknown

Annual Revenue

Not Disclosed (2026)

Office Locations

  • Phoenix, Arizona, USA (U.S. commercial headquarters)
  • Ra'anana, Israel (R&D and original founding office)

Global Reach

30 countries

FDA-Compliant Solutions
Community Contributed
No Sponsored Rankings
Updated Weekly

PharmaSpotter

Comprehensive directory of pharmaceutical software solutions. QMS, LIMS, MES, analytics, and compliance tools for FDA-regulated manufacturing environments.

22 Solution Categories•Curated Data

Software Categories

  • Quality Management Systems
  • Manufacturing Execution Systems
  • Lab Information Management
  • Electronic Batch Records
  • CAPA & Deviation Management
  • Change Control
  • View All Categories →

Resources

  • RFP Template
  • Vendor Scorecard
  • Compliance Guide
  • Implementation Timeline
  • Contribute Data
© 2025 PharmaSpotter. All rights reserved.
Curated pharmaceutical software directory for FDA-regulated manufacturing environments
AboutContactContribute•Privacy PolicyTermsDisclaimer